Intrinsiqq
Jade Biosciences Inc. logo

Jade Biosciences Inc.

JBIO

⊜ Compare

Valuation & Multiples

Based on TTM earnings · Diluted shares

Market Cap$957M
EPS-$1,802.37
P/E-0.01
P/FCF-7.74
EV/EBITDA-3.01
FCF Yield–
Div. Yield–
Net Debt/FCF3.7x
Jade Biosciences Inc. intrinsic value
52-Week Range
$8.95$26.85

Profitability & Returns

Revenue

N/A

Net Income (TTM)

-$153M

▼ -83.0% YoY

Op. Margin

–

ROIC

-41.60%

▲ +5.4pp YoY

Cash Flow & Balance Sheet

FCF (TTM)

-$124M

▼ -33.3% YoY

Op. Cash Flow (TTM)

-$124M

▼ -33.0% YoY

Net Debt

-$460M

Net Cash Position

Cash & Equiv.

$461M

Continue Research

Peers

Pharmaceutical Preparations · Pick stocks to compare with JBIO

CompareIntrinsic value
NTHINeonC Technologies Holdings
$3.17+3.26%10
SLNSilence Therapeutics plc
$19.80+0.10%10
SEPNSepterna, Inc.
$47.88+9.57%46
AXSMAxsome Therapeutics, Inc.
$137.00-1.87%10
NKTXNkarta Inc.
$1.73+13.07%10
TNXPTonix Pharmaceuticals Holding Corp
$5.11-1.54%40
SCYXScynexis, Inc.
$3.84-2.54%40
HROWHarrow Inc.
$28.75+0.74%46

Held by ETFs

JBIO is in 16 US ETFs. The largest of them, with JBIO's weight in each:

Jade Biosciences (JBIO) in two numbers

Dividend
None
No dividend in the SEC filings we hold.
Dividends
P/E
-0.01
Negative: a loss over the last twelve months. Price to free cash flow -7.74.
Financials

Questions about Jade Biosciences

Does Jade Biosciences (JBIO) pay a dividend?

No. Jade Biosciences (JBIO) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.

Source: 10-Q filed 3 Aug 2026 (period ending 30 Jun 2026), SEC. Price: last close 4 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.

Spot a number that looks wrong? Check it in JBIO's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing JBIO

Create a free account and get 14 days of Premium: every stock and every tool.

  • Unlimited stocks
  • Stock screener
  • Portfolio tracker
  • Editable DCF
  • Compare side by side
  • Unlimited alerts

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.